Sophie Park, MD, Grenoble Alpes Hospital, Grenoble, France, discusses the use of erythropoietin-stimulating agents (ESAs) for the management of lower-risk myelodysplastic syndromes (MDS), outlining key studies of interest. Prof. Park discusses the EMA approval of epoetin alfa in patients with lower-risk MDS, as well as the variety of ESAs which are currently under investigation and the optimal use of ESAs to maximize response rate. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.